Tag: Celyad (CYAD)

About the Celyad/Horizon discovery agreement

About the Celyad/Horizon discovery agreement

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. The encouragement came from data emanating from preclinical studies demonstrating the versatility of the shRNA platform in the allogeneic setting. The data is expected to be presented at the upcoming 2018 Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., …
Today’s Highlighted news is from …

Today’s Highlighted news is from …

Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm with promising news focuses on creating and developing safer and far-reaching Chimeric Antigen Receptor T-cell (CAR T) Therapy.   The firm we are highlighting today is Celyad (CYAD), whose investigational CAR T products are allogeneic, rather than autologous, which makes it easier to use and less expensive than the autologous products. …
Why Celyad’s stock gained $2.30 today

Why Celyad’s stock gained $2.30 today

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including  solid tumors. Celyad announced its consolidated financial results for the six-month period ending 30 June 2018. Celyad’s report is endorsed by Europe. Dr. Christian Homsy, Celyad’s CEO started by expressing the firm’s great enthusiasm towards the progress it has made in the first half of 2018, which include a significant advancement of …
Gilead’s CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments

Gilead’s CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments

As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration (FDA) has given the green light to a second CART immuno-oncology product with the trade name Yescarta.  This drug, which has been developed by Kite Pharma is now belonging to Gilead Sciences (GILD) together with the rest of Kite’s CAR T wealthy pipeline after Gilead acquired Kite less than …
New Breakthrough Immuno-Oncology Products

New Breakthrough Immuno-Oncology Products

The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthrough immuno-­oncology treatment outcomes. Here are some of the breakthrough technologies and treatments that might improve, by-­far, the management of cancer . . . This content is for paid subscribers. Please click here to …
Seattle Genetics Announced Impressive News as Did Celyad

Seattle Genetics Announced Impressive News as Did Celyad

Realizing the dream of approval of a small biotech’s lead drug would usually lead a small development-stage firm to either walking on the road to more achievements and growth, or walking in place doing nothing but spending its revenues while no dream materializes. We have seen both possibilities occur time and time again.     Seattle Genetics (SGEN) is now a revenue generating biotech. The firm, which …
Prohost Letter #410

Prohost Letter #410

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the stocks of the drugs’ developing firms. Sending Complete Response Letters for demands that might delay approvals would cut a substantial percentage of the stocks’ values, while rejections would cause the stocks to falter. Let’s …
Bluebird Flies Sky-High with Its CAR-T Wings

Bluebird Flies Sky-High with Its CAR-T Wings

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients in the clinical trial of its chimeric antigen receptor T cell (CAR-T) drug “bb2121 responded to treatment. Data were convincing demonstrating 89% of the patients observed their tumors shrink with 27% seeing their …
CAR-T Great News and About the Biotech Sector in General

CAR-T Great News and About the Biotech Sector in General

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and efficacy on solid cancers are being pursued by academia as well as by biotechnology and pharmaceutical companies. Kite Pharma’s (KITE) CAR-T therapy axicabtagene ciloleucel is an investigational therapy in which …
Prohost Letter #409

Prohost Letter #409

Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. The Meeting, which will begin on Friday June 2, 2017 and will end on Monday 5, 2017 will be different than the past years for many reasons, including the following: -­ Checkpoint inhibition as Immunotherapy for cancer treatment moved from wishful thinking a decade ago, to promising cancer treatments …
Novartis Agreements with Celyad and Bluebird Bio Say a Lot

Novartis Agreements with Celyad and Bluebird Bio Say a Lot

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). The signing of the agreements, enabled Novartis to license the two firm’s proprietary technologies, both related to improving Novartis’ genetically engineered immunooncology CAR- T cells. CELYAD The Celyad/Novartis Agreement Celyad announced a non-exclusive license agreement with Novartis for its US patents issued for the production of allogeneic CAR-T cells. …
Prohost Letter #408

Prohost Letter #408

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the Past issue #407, we picked the following firms: NEUROCRINE BIOSCIENCES (NBIX) Treating Tardive Dyskinesia CYTOMX Improving On Cancer Immunotherapy CELYAD SA (CYAD) Bringing Solutions To Immunotherapy Problems Please Read the articles written about these firms in the Issue #407 In This Issue We Add  NEW LINK GENETICS...
Prohost Letter #407

Prohost Letter #407

Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES   On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its …
CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

CAR-T Immunotherapy Improvement. A Novel Approach and the Firm Behind It

CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the article about checkpoint inhibition as cancer immunotherapy, the approaches that aim at enabling the immune system to fight cancer cells were created to stay and improve and become the gold standard for cancer treatment. Chimeric antigen receptor T cell (CAR-T) therapeutics are speeding their way towards approval in 2017. …
While You Were Sleeping

While You Were Sleeping

A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded a deal worth over $300 million with Ono Pharmaceutical. The deal gives Ono the rights to Celyad’s allogeneic NKR-2 T-cell immunotherapy in Japan, Korea and Taiwan. This news did not mean a lot to investors as Celyad had yet to recover from a heartbreaking  setback in a late phase trial …